FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360864650> ?p ?o ?g. }

• W4360864650 endingPage "644" @default.
• W4360864650 startingPage "644" @default.
• W4360864650 abstract "Acinetobacter baumannii is a Gram-negative organism listed as an urgent threat pathogen by the World Health Organization (WHO). Carbapenem-resistant A. baumannii (CRAB), especially, present therapeutic challenges due to complex mechanisms of resistance to β-lactams. One of the most important mechanisms is the production of β-lactamase enzymes capable of hydrolyzing β-lactam antibiotics. Co-expression of multiple classes of β-lactamases is present in CRAB; therefore, the design and synthesis of “cross-class” inhibitors is an important strategy to preserve the efficacy of currently available antibiotics. To identify new, nonclassical β-lactamase inhibitors, we previously identified a sulfonamidomethaneboronic acid CR167 active against Acinetobacter-derived class C β-lactamases (ADC-7). The compound demonstrated affinity for ADC-7 with a Ki = 160 nM and proved to be able to decrease MIC values of ceftazidime and cefotaxime in different bacterial strains. Herein, we describe the activity of CR167 against other β-lactamases in A. baumannii: the cefepime-hydrolysing class C extended-spectrum β-lactamase (ESAC) ADC-33 and the carbapenem-hydrolyzing OXA-24/40 (class D). These investigations demonstrate CR167 as a valuable cross-class (C and D) inhibitor, and the paper describes our attempts to further improve its activity. Five chiral analogues of CR167 were rationally designed and synthesized. The structures of OXA-24/40 and ADC-33 in complex with CR167 and select chiral analogues were obtained. The structure activity relationships (SARs) are highlighted, offering insights into the main determinants for cross-class C/D inhibitors and impetus for novel drug design." @default.
• W4360864650 created "2023-03-25" @default.
• W4360864650 creator A5000611736 @default.
• W4360864650 creator A5001218502 @default.
• W4360864650 creator A5001525983 @default.
• W4360864650 creator A5007827494 @default.
• W4360864650 creator A5012744793 @default.
• W4360864650 creator A5020890883 @default.
• W4360864650 creator A5022952204 @default.
• W4360864650 creator A5026715391 @default.
• W4360864650 creator A5028655167 @default.
• W4360864650 creator A5031991200 @default.
• W4360864650 creator A5032336593 @default.
• W4360864650 creator A5037850162 @default.
• W4360864650 creator A5064299843 @default.
• W4360864650 creator A5064872874 @default.
• W4360864650 creator A5074635543 @default.
• W4360864650 creator A5082625579 @default.
• W4360864650 creator A5058792172 @default.
• W4360864650 date "2023-03-24" @default.
• W4360864650 modified "2023-09-27" @default.
• W4360864650 title "Sulfonamidoboronic Acids as “Cross-Class” Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance in Acinetobacter baumannii" @default.
• W4360864650 cites W1872459886 @default.
• W4360864650 cites W1968310807 @default.
• W4360864650 cites W1972994991 @default.
• W4360864650 cites W1991952473 @default.
• W4360864650 cites W2006922696 @default.
• W4360864650 cites W2016230165 @default.
• W4360864650 cites W2025930267 @default.
• W4360864650 cites W2028169342 @default.
• W4360864650 cites W2031903144 @default.
• W4360864650 cites W2065485664 @default.
• W4360864650 cites W2083974126 @default.
• W4360864650 cites W2087126312 @default.
• W4360864650 cites W2094208194 @default.
• W4360864650 cites W2095666577 @default.
• W4360864650 cites W2095685393 @default.
• W4360864650 cites W2116732925 @default.
• W4360864650 cites W2124026197 @default.
• W4360864650 cites W2132407531 @default.
• W4360864650 cites W2143660875 @default.
• W4360864650 cites W2143874510 @default.
• W4360864650 cites W2163341755 @default.
• W4360864650 cites W2226714711 @default.
• W4360864650 cites W2565816470 @default.
• W4360864650 cites W2728041751 @default.
• W4360864650 cites W2737879351 @default.
• W4360864650 cites W2749553794 @default.
• W4360864650 cites W2768132128 @default.
• W4360864650 cites W2768793412 @default.
• W4360864650 cites W2771721896 @default.
• W4360864650 cites W2779019546 @default.
• W4360864650 cites W2970048441 @default.
• W4360864650 cites W3010223436 @default.
• W4360864650 cites W3010674904 @default.
• W4360864650 cites W3012097929 @default.
• W4360864650 cites W3085250904 @default.
• W4360864650 cites W3089906564 @default.
• W4360864650 cites W3092579029 @default.
• W4360864650 cites W3106144746 @default.
• W4360864650 cites W3130074412 @default.
• W4360864650 cites W3133065925 @default.
• W4360864650 cites W4213133581 @default.
• W4360864650 cites W4282834160 @default.
• W4360864650 doi "https://doi.org/10.3390/antibiotics12040644" @default.
• W4360864650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37107006" @default.
• W4360864650 hasPublicationYear "2023" @default.
• W4360864650 type Work @default.
• W4360864650 citedByCount "0" @default.
• W4360864650 crossrefType "journal-article" @default.
• W4360864650 hasAuthorship W4360864650A5000611736 @default.
• W4360864650 hasAuthorship W4360864650A5001218502 @default.
• W4360864650 hasAuthorship W4360864650A5001525983 @default.
• W4360864650 hasAuthorship W4360864650A5007827494 @default.
• W4360864650 hasAuthorship W4360864650A5012744793 @default.
• W4360864650 hasAuthorship W4360864650A5020890883 @default.
• W4360864650 hasAuthorship W4360864650A5022952204 @default.
• W4360864650 hasAuthorship W4360864650A5026715391 @default.
• W4360864650 hasAuthorship W4360864650A5028655167 @default.
• W4360864650 hasAuthorship W4360864650A5031991200 @default.
• W4360864650 hasAuthorship W4360864650A5032336593 @default.
• W4360864650 hasAuthorship W4360864650A5037850162 @default.
• W4360864650 hasAuthorship W4360864650A5058792172 @default.
• W4360864650 hasAuthorship W4360864650A5064299843 @default.
• W4360864650 hasAuthorship W4360864650A5064872874 @default.
• W4360864650 hasAuthorship W4360864650A5074635543 @default.
• W4360864650 hasAuthorship W4360864650A5082625579 @default.
• W4360864650 hasBestOaLocation W43608646501 @default.
• W4360864650 hasConcept C185592680 @default.
• W4360864650 hasConcept C21951064 @default.
• W4360864650 hasConcept C2776315533 @default.
• W4360864650 hasConcept C2776685102 @default.
• W4360864650 hasConcept C2776968632 @default.
• W4360864650 hasConcept C2777050379 @default.
• W4360864650 hasConcept C2777637488 @default.
• W4360864650 hasConcept C2778523567 @default.
• W4360864650 hasConcept C2778719061 @default.
• W4360864650 hasConcept C2779631663 @default.

• next